10x Genomics Files Q3 2024 10-Q

TL;DR

**10x Genomics Q3 2024 10-Q filed. Financials and ops details inside.**

AI Summary

10x Genomics, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter of 2024. Specific financial figures and strategic developments are outlined within the report.

Why It Matters

This filing provides investors with the latest financial health and operational performance of 10x Genomics, crucial for understanding the company's trajectory in the life sciences sector.

Risk Assessment

Risk Level: medium — 10-Q filings are standard disclosures, but the specific financial performance and forward-looking statements within can indicate varying levels of risk.

Key Numbers

• 2024 Q3 — Fiscal Quarter (Reporting period for the 10-Q)
• 2024-09-30 — Period End Date (The date through which financial information is reported)
• 2023-12-31 — Previous Year End Date (For comparative financial analysis)

Key Players & Entities

• 10x Genomics, Inc. (company) — Filer of the 10-Q report
• 20240930 (date) — End of the reporting period
• 20241029 (date) — Date of filing and change

FAQ

Key Financial Figures

• $0.00001 — stered Class A common stock, par value $0.00001 per share TXG The Nasdaq Stock Market L

Filing Documents

• txg-20240930.htm (10-Q) — 970KB
• txg-20240930xex1011.htm (EX-10.1) — 226KB
• txg-20240930xex1012.htm (EX-10.1) — 203KB
• txg-20240930xex1021.htm (EX-10.2) — 98KB
• txg-20240630xex103.htm (EX-10.3) — 133KB
• txg-20240930xex311.htm (EX-31.1) — 9KB
• txg-20240930xex312.htm (EX-31.2) — 9KB
• txg-20240930xex321.htm (EX-32.1) — 5KB
• txg-20240930xex322.htm (EX-32.2) — 5KB
• a10x_logoxverticalxfullcola.jpg (GRAPHIC) — 35KB
• imagea.jpg (GRAPHIC) — 2KB
• txg-20240930_g1.jpg (GRAPHIC) — 223KB
• 0001770787-24-000073.txt ( ) — 6627KB
• txg-20240930.xsd (EX-101.SCH) — 32KB
• txg-20240930_cal.xml (EX-101.CAL) — 72KB
• txg-20240930_def.xml (EX-101.DEF) — 135KB
• txg-20240930_lab.xml (EX-101.LAB) — 505KB
• txg-20240930_pre.xml (EX-101.PRE) — 329KB
• txg-20240930_htm.xml (XML) — 707KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Loss 5 Condensed Consolidated Statements of Stockholders' Equity 6 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 26 Item 4.

Controls and Procedures

Controls and Procedures 26 PART II. OTHER INFORMATION 27 Item 1.

Legal Proceedings

Legal Proceedings 27 Item 1A.

Risk Factors

Risk Factors 27 Item 5. Other Information 27 Item 6. Exhibits 27

Signatures

Signatures 30 Table of Contents 10x Genomics, Inc. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Quarterly Report") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are subject to those sections' "safe harbor." All statements, other than historical facts, may be forward-looking statements. Forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or variations of these terms or similar terminology generally can identify forward-looking statements, but the absence of these words is not determinative. These forward-looking statements include statements regarding 10x Genomics, Inc.'s expectations regarding our plans, objectives, goals, beliefs, business strategies, results of operations, financial position, sufficiency of our capital resources, business outlook, future events, business conditions, key business metrics and key factors affecting our performance, gross margin, organization, business and other trends, expected future investments including anticipated capital expenditures, anticipated size of market opportunities and our ability to capture them, expected uses, performance and benefits of our products and services and other information. These statements are based on management's expectations, forecasts, beliefs, opinions, assumptions and information available at the time of filing and should not be relied upon as 10x Genomics, Inc.'s views as of any subsequent date. Actual outcomes and results could differ materially from these statements due to several factors. 10x Geno

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. 10x Genomics, Inc. Condensed Consolidated Balance Sheets (In thousands) September 30, 2024 December 31, 2023 (Unaudited) (Note 1) Assets Current assets: Cash and cash equivalents $ 398,159 $ 359,284 Marketable securities — 29,411 Accounts receivable, net 83,525 114,832 Inventory 94,050 73,706 Prepaid expenses and other current assets 18,159 18,789 Total current assets 593,893 596,022 Property and equipment, net 258,759 279,571 Operating lease right-of-use assets 59,579 65,361 Goodwill 4,511 4,511 Intangible assets, net 16,149 16,616 Other noncurrent assets 4,903 3,062 Total assets $ 937,794 $ 965,143 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 26,210 $ 15,738 Accrued compensation and related benefits 30,080 30,105 Accrued expenses and other current liabilities 37,770 56,648 Deferred revenue 17,760 13,150 Operating lease liabilities 9,415 11,521 Total current liabilities 121,235 127,162 Operating lease liabilities, noncurrent 76,461 83,849 Deferred revenue, noncurrent 12,349 8,814 Other noncurrent liabilities 4,945 4,275 Total liabilities 214,990 224,100 Commitments and contingencies (Note 4) Stockholders' equity: Preferred stock — — Common stock 2 2 Additional paid-in capital 2,140,789 2,025,890 Accumulated deficit ( 1,418,019 ) ( 1,284,420 ) Accumulated other comprehensive income (loss) 32 ( 429 ) Total stockholders' equity 722,804 741,043 Total liabilities and stockholders' equity $ 937,794 $ 965,143 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 Table of Contents 10x Genomics, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share data) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Revenue $ 151,654 $ 153,644 $ 445,764 $ 434,748 Cost of revenue 45,261 58,115 142,237 141,217 Gross profit

View Full Filing

View this 10-Q filing on SEC EDGAR